BRETT CARTER to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications BRETT CARTER has written about Antibodies, Monoclonal, Humanized.
Connection Strength
0.105
-
Outcomes to first-line pembrolizumab in patients with PD-L1-high (=50%) non-small cell lung cancer and a poor performance status. J Immunother Cancer. 2020 08; 8(2).
Score: 0.085
-
Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. J Thorac Oncol. 2020 02; 15(2):248-257.
Score: 0.020